Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Oral Nano-Curcumin Formulation Efficacy in the Management of Mild to Moderate Outpatient Covid-19: A Randomized Triple-Blind Placebo-Controlled Clinical Trial Publisher



Ahmadi R1 ; Salari S2 ; Sharifi MD3, 4 ; Reihani H3, 4 ; Rostamiani MB2 ; Behmadi M3, 4 ; Taherzadeh Z5 ; Eslami S6 ; Rezayat SM7 ; Jaafari MR8, 9 ; Elyasi S1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Family Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  2. 2. Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
  3. 3. Faculty of Medicine, Department of Emergency Medicine, Mashhad University of Medical sciences, Mashhad, Iran
  4. 4. Department of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  5. 5. Targeted Drug Delivery Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
  6. 6. Faculty of Medicine, Department of Medical Informatics, Mashhad University of Medical Sciences, Mashhad, Iran
  7. 7. Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  8. 8. Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
  9. 9. Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Source: Food Science and Nutrition Published:2021


Abstract

Background: Curcumin, a natural polyphenolic compound, is proposed as a potential treatment option for patients with coronavirus disease by inhibiting the entry of virus to the cell, encapsulation of the virus and viral protease, as well as modulating various cellular signaling pathways. In this study, the efficacy and safety of nanocurcumin oral formulation has been evaluated in patients with mild-moderate Coronavirus disease 2019 (COVID-19) in outpatient setting. Methods: In this triple-blind randomized placebo-controlled clinical trial, sixty mild to moderate COVID-19 patients in outpatient setting who fulfilled the inclusion criteria were randomly allocated to treatment (n = 30) group to receive oral nanocurcumin formulation (Sinacurcumin soft gel which contains 40 mg curcuminoids as nanomicelles), two soft gels twice a day after food for 2 weeks or placebo (n = 30) group. Patients’ symptoms and laboratory data were assessed at baseline and during follow-up period and compared between two groups. Results: All symptoms except sore throat resolved faster in the treatment group and the difference was significant for chills, cough and smell and taste disturbances. The CRP serum level was lower in the treatment group at the end of two weeks and the lymphocyte count was significantly higher in treatment group. No significant adverse reaction reported in the treatment group. Conclusion: Oral nanoformulation of curcumin can significantly improve recovery time in patients with mild to moderate COVID-19 in outpatient setting. Further studies with larger sample size are recommended. © 2021 The Authors. Food Science & Nutrition published by Wiley Periodicals LLC.
Other Related Docs
14. Immune-Based Therapeutic Approaches in Covid-19, Biomedicine and Pharmacotherapy (2022)
21. Analyzing Trends in Demographic, Laboratory, Imaging, and Clinical Outcomes of Icu-Hospitalized Covid-19 Patients, Canadian Journal of Infectious Diseases and Medical Microbiology (2023)
26. Jak Inhibition As a New Treatment Strategy for Patients With Covid-19, International Archives of Allergy and Immunology (2020)
30. Molecular Aspects of Co-Morbidities in Covid-19 Infection, Archives of Bone and Joint Surgery (2020)
31. Covid-19 in Patients With Diabetes: Factors Associated With Worse Outcomes, Journal of Diabetes and Metabolic Disorders (2021)